Global Cancer Monoclonal Antibodies Market Report 2024

Cancer Monoclonal Antibodies Global Market Report 2024 – By Monoclonal Antibody Therapies (Avastin, Herceptin, Keytruda, Opdivo, Darzalex, Perjeta, Others), By Application (Breast Cancer, Blood Cancer, Lung Cancer, Brain Tumor, Colorectal Cancer, Cervical Cancer, Gastric Cancer, Others), By End-User (Hospitals, Research Laboratories, Others) – Market Size, Trends, And Global Forecast 2024-2033

Starting Price : $5000.00 | Pages : 250 | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Cancer Monoclonal Antibodies Market

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Cancer Monoclonal Antibodies Market Definition And Segments

Cancer monoclonal antibodies refer to a particular class of protein created in a lab that has the ability to bind to certain bodily targets, such as antigens on the surface of cancer cells. Each monoclonal antibody is designed to bind to a single antigen, and there are many different types of monoclonal antibodies.

The main types of monoclonal antibody therapies in cancer are bevacizumab (Avastin), rituximab (Rituxan), trastuzumab (Herceptin), cetuximab (Erbitux), and panitumumab (Vectibix). Avastin is a medication that helps people with wet age-related macular degeneration (AMD). It can also be employed to treat diabetic eye problems and other retinal issues. It's administered into the eye to help delay the loss of eyesight caused by certain disorders. The different applications include breast cancer, blood cancer, liver cancer, brain cancer, colorectal cancer, and others, and involve various sectors such as hospitals and clinics, research laboratories, pharmacies, and others.

The cancer monoclonal antibodies market covered in this report is segmented –

1) By Monoclonal Antibody Therapies: Avastin, Herceptin, Keytruda, Opdivo, Darzalex, Perjeta, Others

2) By Application: Breast Cancer, Blood Cancer, Lung Cancer, Brain Tumor, Colorectal Cancer, Cervical Cancer, Gastric Cancer, Others

3) By End-User: Hospitals, Research Laboratories, Others

The cancer monoclonal antibodies market size has grown rapidly in recent years. It will grow from $59.98 billion in 2023 to $66.1 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to emerging markets growth, increase in R&D expenditure, increased geriatric population, and increased preference for biological treatments.

The cancer monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $95.99 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to the increasing prevalence of cancer, expanding global access, and a rise in healthcare expenditure will drive the growth. Major trends in the forecast period include product innovation through strategic collaborations, technological advancements, developing humanized cancer monoclonal antibodies, investments in AI to reduce R&D costs and save drug development time, and R&D investments.

Cancer Monoclonal Antibody Market Driven By Rising Cancer Incidence Rates

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer monoclonal antibody market. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. Therefore, the rise in the cancer incidence rate globally is anticipated to boost the demand for growth of the cancer monoclonal antibody market.

Rising Healthcare Expenditures Expected To Propel Cardiovascular Device Market Growth

Increasing healthcare expenditures are anticipated to propel the growth of the Cancer Monoclonal Antibodies market. Healthcare expenditures refer to the total amount spent on healthcare-related services, products, and activities within a specified period, typically on an individual, community, national, or global level. The higher funding in healthcare can support the development, accessibility, and research of monoclonal antibody treatments, while also enabling the adoption of advanced technologies for their production and delivery. For instance, in May 2023, the Office for National Statistics, a UK-based statistics authority, reported that healthcare spending in the UK increased by 9.4% in nominal terms and 9.7% in real terms. UK total healthcare expenditure in 2021 was $367.25 billion (£280.7 billion), and pharmaceutical expenditure was $51.84 billion (£39.6 billion) in 2021. Furthermore, spending on preventive care was $45.93 billion (£35.1 billion) in 2021, more than doubling from the previous year. Therefore, increasing healthcare expenditure will drive the growth of the cancer monoclonal antibodies market going forward.

Major companies operating in the cancer monoclonal antibodies market report are F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol Myers Squibb Company, Johnson & Johnson, Amgen Inc., AstraZeneca PLC, Eli Lilly and Company, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A, Innovent Biologics, Sino biological, Shanghai Henlius Biotech, Intas bio, Zydus Cadila, Ranbaxy, Takeda pharmaceuticals, AbbVie Inc., Biogen Idec, Bayer AG, Novartis AG, BiosanaPharma, WuXi, GlaxoSmithKline, Teva UK Limited, Abbott Laboratories, Fujifilm, Procos SpA, BSP Pharmaceuticals, Genmab, Insysbio, Rani Therapeutics, Emisphere Technologies, Inc., Enteris BioPharma, Allena Pharmaceuticals, Apotex, Gilead Sciences, Eurofarma, Teuto Brasileiro, BioMarin Pharmaceutical, BIONOVIS BRASIL, Ecopharm, Hypermarcas, Ache, Libbs Farmaceutica, Julphar, Spimaco Addwaeih, Hikma Pharmaceuticals, Tabuk, Novo Nordisk, BBI Solutions, APC Pharma, EPICIO, Medical Union Pharmaceuticals, South Egypt Drug Industries Co. Pharmaceutical, Vacsera Pharma, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd., 54gene, Baxter International, Altis Biologics, Cipla Medpro South Africa, Genzyme

High Development Costs Of Advanced Techniques Restraining Growth In The Cancer Monoclonal Antibodies Market

The high costs involved in the development of monoclonal antibodies with advanced techniques act as a major restraint on the market due to the complex production process, expensive biological and chemical materials, and clinical trials, as well as the required safety, efficacy, and quality tests. Advanced equipment is required for the large-scale production of monoclonal antibodies that encompass multiple disulfide bonds and post-translational modifications, and this equipment is expensive. Clinical efficacy is usually achieved by injecting large amounts of monoclonal antibodies into the system, which means that large quantities are required to be produced for each treatment, thus increasing the cost. According to the American Journal of Managed Care, the annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than that of those used in other disease states. Thus, the high development costs of using these advanced techniques will restrain the cancer monoclonal antibodies market growth.

Collaborative Innovation To Develop Breakthrough Therapies

Companies in the cancer monoclonal antibody market are increasing their product innovation through strategic collaborations. To sustain themselves in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with academic and research institutions in this market by way of partnerships and in- or out-licensing deals, this trend has been increasing over the past few years. For instance, in March 2023, BioNTech SE, a Germany-based biotechnology research company, partnered with OncoC4, Inc. to jointly develop and market an innovative checkpoint antibody across various solid tumor indications. Through this partnership, BioNTech will obtain an exclusive worldwide license for the ONC-392 anti-CTLA-4 monoclonal antibody from OncoC4. Joint Development Planned for Solid Tumor Indications, Including a Phase 3 Trial in 2023 BioNTech to Explore Combination Therapies and Provide $200 Million Upfront Payment and Royalty Payments to OncoC4 with Potential Milestone OncoC4, Inc. is a US-based clinical-stage biopharmaceutical company specializing in biologicals for cancer treatment.

EPKINLY Advances Lymphoma Treatment

Companies operating in the cancer monoclonal antibodies market are focused on new biologic therapies such as EPKINLY to sustain their position in the market. EPKINLY is an FDA-approved bispecific antibody for advanced lymphoma treatment. For instance, in May 2023, AbbVie Inc., a US-based biopharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for EPKINLY (epcoritamab-bysp). It is the first and only T-cell engaging bispecific antibody designed for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma (HGBL) who have undergone two or more rounds of systemic therapies.

Pfizer's Strategic Acquisition Of Trillium Therapeutics Strengthens Cancer Immunotherapy Portfolio

In November 2021, Pfizer Inc., a US-based pharmaceutical and biotechnology company, acquired Trillium Therapeutics for $2.22 billion. With this acquisition, Pfizer aims to expand its portfolio of biologics that enhance the innate immune system to fight both hematological malignancies and solid tumors. Trillium Therapeutics is a Canada-based biopharmaceutical company focused on developing innovative immunotherapies and antibody programs for the treatment of cancer.

North America was the largest region in the cancer monoclonal antibodies market in 2023. The regions covered in the cancer monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the cancer monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The cancer monoclonal antibody market consists of sales of pembrolizumab, blinatumomab, casirivimab, and imdevimab. Values in this market are ""factory gate values,"" that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The cancer monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides cancer monoclonal antibodies market statistics, such as cancer monoclonal antibodies industry global market size, regional shares, competitors with a cancer monoclonal antibodies market share, detailed cancer monoclonal antibodies market segments, market trends and opportunities, and any other information you may require to thrive in the ca This cancer monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Cancer Monoclonal Antibodies Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $66.1 billion
Revenue Forecast In 2033 $95.99 billion
Growth Rate CAGR of 9.8% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Monoclonal Antibody Therapies: Avastin, Herceptin, Keytruda, Opdivo, Darzalex, Perjeta, Others
2) By Application: Breast Cancer, Blood Cancer, Lung Cancer, Brain Tumor, Colorectal Cancer, Cervical Cancer, Gastric Cancer, Others
3) By End-User: Hospitals, Research Laboratories, Others
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled F. Hoffmann-La Roche Ltd; Merck & Co., Inc; Bristol Myers Squibb Company; Johnson & Johnson; Amgen Inc; AstraZeneca plc; Eli Lilly and Company; Pfizer Inc; Regeneron Pharmaceuticals Inc; Sanofi S.A; Innovent Biologics; Sino biological; Shanghai Henlius Biotech; Intas bio; Zydus Cadila; Ranbaxy; Takeda pharmaceuticals; AbbVie Inc; Biogen Idec; Bayer AG; Novartis AG; BiosanaPharma; WuXi; GlaxoSmithKline; Teva UK Limited; Abbott Laboratories; Fujifilm; Procos SpA; BSP Pharmaceuticals; Genmab; Insysbio; Rani Therapeutics; Emisphere Technologies, Inc; Enteris BioPharma; Allena Pharmaceuticals; Apotex; Gilead Sciences; Eurofarma; Teuto Brasileiro; BioMarin Pharmaceutical; BIONOVIS BRASIL; Ecopharm; Hypermarcas; Ache; Libbs Farmaceutica; Julphar; Spimaco Addwaeih; Hikma Pharmaceuticals; Tabuk; Novo Nordisk; BBI Solutions; APC Pharma; EPICIO; Medical Union Pharmaceuticals; South Egypt Drug Industries Co. Pharmaceutical; Vacsera Pharma; Aspen Pharmacare; Amoun Pharmaceuticals CO Ltd; 54gene; Baxter International; Altis Biologics; Cipla Medpro South Africa; Genzyme
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Cancer Monoclonal Antibodies Market Characteristics

    3. Cancer Monoclonal Antibodies Market Trends And Strategies

    4. Cancer Monoclonal Antibodies Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global Cancer Monoclonal Antibodies Market Size and Growth

    5.1. Global Cancer Monoclonal Antibodies Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Cancer Monoclonal Antibodies Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Cancer Monoclonal Antibodies Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Cancer Monoclonal Antibodies Market Segmentation

    6.1. Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Bevacizumab (Avastin)

    Rituximab (Rituxan)

    Trastuzumab (Herceptin)

    Cetuximab (Erbitux)

    Panitumumab (Vectibix)

    Other Monoclonal Antibody Therapies

    6.2. Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Breast Cancer

    Blood Cancer

    Liver Cancer

    Brain Cancer

    Colorectal Cancer

    Other Applications

    6.3. Global Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospitals And Clinics

    Research Laboratories

    Pharmacies

    Other End Users

    7. Cancer Monoclonal Antibodies Market Regional And Country Analysis

    7.1. Global Cancer Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Cancer Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Cancer Monoclonal Antibodies Market

    8.1. Asia-Pacific Cancer Monoclonal Antibodies Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Cancer Monoclonal Antibodies Market

    9.1. China Cancer Monoclonal Antibodies Market Overview

    9.2. China Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Cancer Monoclonal Antibodies Market

    10.1. India Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Cancer Monoclonal Antibodies Market

    11.1. Japan Cancer Monoclonal Antibodies Market Overview

    11.2. Japan Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Cancer Monoclonal Antibodies Market

    12.1. Australia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Cancer Monoclonal Antibodies Market

    13.1. Indonesia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Cancer Monoclonal Antibodies Market

    14.1. South Korea Cancer Monoclonal Antibodies Market Overview

    14.2. South Korea Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Cancer Monoclonal Antibodies Market

    15.1. Western Europe Cancer Monoclonal Antibodies Market Overview

    15.2. Western Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Cancer Monoclonal Antibodies Market

    16.1. UK Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Cancer Monoclonal Antibodies Market

    17.1. Germany Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Cancer Monoclonal Antibodies Market

    18.1. France Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.2. France Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.3. France Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Cancer Monoclonal Antibodies Market

    19.1. Italy Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.2. Italy Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.3. Italy Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Cancer Monoclonal Antibodies Market

    20.1. Spain Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.2. Spain Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.3. Spain Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Cancer Monoclonal Antibodies Market

    21.1. Eastern Europe Cancer Monoclonal Antibodies Market Overview

    21.2. Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Cancer Monoclonal Antibodies Market

    22.1. Russia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Cancer Monoclonal Antibodies Market

    23.1. North America Cancer Monoclonal Antibodies Market Overview

    23.2. North America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Cancer Monoclonal Antibodies Market

    24.1. USA Cancer Monoclonal Antibodies Market Overview

    24.2. USA Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Cancer Monoclonal Antibodies Market

    25.1. Canada Cancer Monoclonal Antibodies Market Overview

    25.2. Canada Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Cancer Monoclonal Antibodies Market

    26.1. South America Cancer Monoclonal Antibodies Market Overview

    26.2. South America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Cancer Monoclonal Antibodies Market

    27.1. Brazil Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Cancer Monoclonal Antibodies Market

    28.1. Middle East Cancer Monoclonal Antibodies Market Overview

    28.2. Middle East Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Cancer Monoclonal Antibodies Market

    29.1. Africa Cancer Monoclonal Antibodies Market Overview

    29.2. Africa Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Cancer Monoclonal Antibodies Market Competitive Landscape And Company Profiles

    30.1. Cancer Monoclonal Antibodies Market Competitive Landscape

    30.2. Cancer Monoclonal Antibodies Market Company Profiles

    30.2.1. F. Hoffmann-La Roche Ltd

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Merck & Co., Inc

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Bristol Myers Squibb Company

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Johnson & Johnson

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Amgen Inc

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Cancer Monoclonal Antibodies Market Other Major And Innovative Companies

    31.1. AstraZeneca plc

    31.2. Eli Lilly and Company

    31.3. Pfizer Inc

    31.4. Regeneron Pharmaceuticals Inc

    31.5. Sanofi S.A

    31.6. Innovent Biologics

    31.7. Sino biological

    31.8. Shanghai Henlius Biotech

    31.9. Intas bio

    31.10. Zydus Cadila

    31.11. Ranbaxy

    31.12. Takeda pharmaceuticals

    31.13. AbbVie Inc

    31.14. Biogen Idec

    31.15. Bayer AG

    32. Global Cancer Monoclonal Antibodies Market Competitive Benchmarking

    33. Global Cancer Monoclonal Antibodies Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The Cancer Monoclonal Antibodies Market

    35. Cancer Monoclonal Antibodies Market Future Outlook and Potential Analysis

    35.1 Cancer Monoclonal Antibodies Market In 2028 - Countries Offering Most New Opportunities

    35.2 Cancer Monoclonal Antibodies Market In 2028 - Segments Offering Most New Opportunities

    35.3 Cancer Monoclonal Antibodies Market In 2028 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Cancer Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Cancer Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: F. Hoffmann-La Roche Ltd Financial Performance
  • Table 75: Merck & Co., Inc Financial Performance
  • Table 76: Bristol Myers Squibb Company Financial Performance
  • Table 77: Johnson & Johnson Financial Performance
  • Table 78: Amgen Inc Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Cancer Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Cancer Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: F. Hoffmann-La Roche Ltd Financial Performance
  • Figure 75: Merck & Co., Inc Financial Performance
  • Figure 76: Bristol Myers Squibb Company Financial Performance
  • Figure 77: Johnson & Johnson Financial Performance
  • Figure 78: Amgen Inc Financial Performance
Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company
Read More
Global Gene Therapy Market 2022 – Market Opportunities And Strategies
Read More
The Microbiome Market Share, Market Size, And Growth Rate 2022
Read More
Latest TNF Alpha Inhibitors Market Growth Study 2022-2026 By The Business Research Company
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the dermatitis market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the insulin drugs market research report 2022 with industry size, share, segments and market growth
Read More
Point-of-Care Diagnostics Devices And Equipment Global Market Report 2024 – By Type (Infectious disease testing kits, Cardio metabolic monitoring kits,, Cholesterol testing kits, Pregnancy and fertility tests kits, Tumor/cancer markers, Urinalysis testing kits, Hematology testing kits, Drugs of abuse testing kits, Fecal occult testing kits, Other Types), By Prescription Mode (Prescription-based Testing Devices, Over-The-Counter (OTC) Testing Devices), By End User (Professional diagnostic centers, Hospitals/critical care centers, Outpatient healthcare Setting, Ambulatory care settings, Research laboratories, Home) – Market Size, Trends, And Global Forecast 2024-2033
View Report
3D Cell Culture Technologies Global Market Report 2024 – By Type (Scaffold-based, Scaffold-free, 3D Bioreactors), By Application (Cancer Research, Stem Cell Research, Drug Discovery, Regenerative Medicine), By End Users (Research Laboratories and Institutes, Biotechnology and Pharmaceutical Companies, Hospitals and Diagnostic Centers, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Metabolomics Global Market Report 2024 – By Product & Service (Metabolomics Instruments, Metabolomics Bioinformatics Tools & Services), By Indication (Cancer, Cardiovascular Disorders, Neurological Disorders, Inborn Errors of Metabolism, Other Indications), By Application (Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics, Personalized Medicine, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Isothermal Nucleic Acid Amplification Technology (INAAT) Global Market Report 2024 – By Product (Instrument, Reagent), By Technology (NASBA, HAD), By Application (Blood Screening, Infectious Disease Diagnostics, Cancer), By End-User (Hospital, Reference Laboratories, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Cancer biologics Global Market Report 2024 – By Type (Monoclonal Antibodies, Vaccines, Cell And Gene Therapy, Other Types), By Application (Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications), By Distribution Channel (Hospitals, Clinics, Other Distribution Channels) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Skin Cancer Drugs Global Market Report 2024 – By Type (Actinic Keratoses (AK), Basal cell carcinoma (BCC), Squamous cell carcinoma (SCC), Melanoma), By Drug Class (Chemotherapy, Immunotherapy, Targeted Agents & Other Drugs), By End Users (Hospitals, Cancer Research Centers, Clinics) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Pancreatic Cancer Drugs Global Market Report 2024 – By Type (Pancreatic Neuroendocrine Cancer Drugs, Pancreatic Exocrine Cancer Drugs), By Drug Combination (Single, Double, Triplet, Quadruplet), By End User (Hospital Pharmacies, Retail Pharmacies, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Breast Cancer Drugs Global Market Report 2024 – By Type (Metastatic Breast Cancer, Triple Negative Breast Cancer, Others (Ductal Carcinoma Insitu, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, Breast Cancer During Pregnancy, Others)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Other Distribution Channels), By End User (Ambulatory, Hospitals, Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report

Frequently Asked Questions

What is the definition of the cancer monoclonal antibodies market?

Cancer monoclonal antibodies refer to a particular class of protein created in a lab that has the ability to bind to certain bodily targets, such as antigens on the surface of cancer cells. Each monoclonal antibody is designed to bind to a single antigen, and there are many different types of monoclonal antibodies. For further insights on the cancer monoclonal antibodies market, request a sample here

How will the cancer monoclonal antibodies market drivers and restraints affect the cancer monoclonal antibodies market dynamics? What forces will shape the cancer monoclonal antibodies industry going forward?

The cancer monoclonal antibodies market growth is aided by rise in the number of cancer cases across the globe. However, some cancer monoclonal antibodies market restraints include high costs involved in the development of monoclonal antibodies with advanced techniques. For further insights on the cancer monoclonal antibodies market, request a sample here

What is the forecast market size or the forecast market value of the cancer monoclonal antibodies market?

The cancer monoclonal antibodies market is expected to reach $98.11 billion in 2027 at a rate of 12.0%. For further insights on the cancer monoclonal antibodies market, request a sample here

How is the cancer monoclonal antibodies market segmented?

The global cancer monoclonal antibodies market is segmented as
1) By Monoclonal Antibody Therapies: Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Other Monoclonal Antibody Therapies
2) By Application: Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Other Applications
3) By End User: Hospitals And Clinics, Research Laboratories, Pharmacies, Other End Users
For further insights on the cancer monoclonal antibodies market, request a sample here

Which region has the largest share of the cancer monoclonal antibodies market? What are the largest region's market size and growth rate?

North America was the largest region in the cancer monoclonal antibodies market in 2022. For detailed insights on the largest region's market size and growth rate, request a sample here.

Who are the major players in the cancer monoclonal antibodies market?

Key competitors in the cancer monoclonal antibodies market are, Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genmab AS, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Merck & Co., Spectrum Pharmaceuticals, Seattle Genetics, Pfizer, Sanofi, Abbvie,  Takeda Pharmaceuticals, Genentech,  AstraZeneca,  Biogen. For further insights on the cancer monoclonal antibodies market, request a sample here.

What are the key trends in the cancer monoclonal antibodies market?

Major trends influencing the cancer monoclonal antibodies market include increasing product innovation through strategic collaborations. To sustain themselves in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with academic and research institutions in this market by way of partnerships and in- or out-licensing deals, this trend has been increasing over the past few years. For further insights on the cancer monoclonal antibodies market, request a sample here.

What are the major opportunities in the cancer monoclonal antibodies market? What are the strategies for the cancer monoclonal antibodies market?

For detailed insights on the major opportunities and strategies in the cancer monoclonal antibodies market, request a sample here.

How does the cancer monoclonal antibodies market relate to the overall economy and other similar markets?

For detailed insights on cancer monoclonal antibodies market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the cancer monoclonal antibodies industry?

For detailed insights on the mergers and acquisitions in the cancer monoclonal antibodies industry, request a sample here.

What are the key dynamics influencing the cancer monoclonal antibodies market growth? SWOT analysis of the cancer monoclonal antibodies market.

For detailed insights on the key dynamics influencing the cancer monoclonal antibodies market growth and SWOT analysis of the cancer monoclonal antibodies industry, request a sample here.